TLSI
TriSalus Life Sciences Inc.NASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$254.25M
P/E Ratio
—
EPS
$-1.92
Beta
0.54
52W High
$7.95
52W Low
$3.42
50-Day MA
$4.59
200-Day MA
$5.06
Dividend Yield
—
Profit Margin
-86.90%
Forward P/E
—
PEG Ratio
—
About TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc. (TLSI) is a cutting-edge biopharmaceutical firm committed to transforming cancer therapies through its proprietary localized drug delivery technologies. By enhancing the efficacy of immuno-oncology agents and overcoming significant distribution barriers within the tumor microenvironment, TriSalus aims to significantly improve patient outcomes in oncology. The company is advancing a robust pipeline of clinical programs that reflect its innovative approach and dedication to addressing the unmet needs of patients with challenging cancers. With a focus on expanding access to effective therapies, TriSalus is well-positioned to make a meaningful impact in the field of cancer treatment.
Fundamentals
| Revenue (TTM) | $45.15M |
| Gross Profit (TTM) | $38.19M |
| EBITDA | $-26.32M |
| Operating Margin | -24.80% |
| Return on Equity | -496.20% |
| Return on Assets | -56.80% |
| Revenue/Share (TTM) | $1.19 |
| Book Value | $-0.68 |
| Price-to-Book | 30.29 |
| Price-to-Sales (TTM) | 5.63 |
| EV/Revenue | 6.08 |
| EV/EBITDA | -5.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 59.80% |
| Shares Outstanding | $61.41M |
| Float | $51.85M |
| % Insiders | 28.21% |
| % Institutions | 19.07% |
Historical Volatility
HV 10-Day
64.59%
HV 20-Day
50.21%
HV 30-Day
55.65%
HV 60-Day
68.78%
HV Rank
30.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($9.20 target)
1
Strong Buy5
BuyData last updated: 4/9/2026